Breaking News

FDA Roundup: December 6, 2022 Lilly Announces Updated Data from the Verzenio® (abemaciclib) Phase 3 monarchE Trial Presented at SABCS and Simultaneously Published in The Lancet Oncology Statement by Assistant Secretary for Mine Safety and Health Williamson recognizing America’s mine workers on National Miners Day Daily Press Briefing by the Office of the Spokesperson for the Secretary-General Wellesley Island Border Patrol Agents and the Jefferson County Sheriff’s Office Seized Approximately 150 Pounds of Marijuana Governor Cooper Announces Alamance Foods Will Expand and Create 135 Jobs FEMA Awards Almost $4.5 Million to Manchester-by-the-Sea to Fight Flooding Readout of Deputy Secretary of Defense Dr. Kathleen H. Hicks’ Meeting With U.K. Permanent Under Secretary of Defence David Williams

Issued: London UK

GSK today identified the non-core OTC brands that it intends to divest as the company focuses its Consumer Healthcare business around a portfolio of fast-growing priority brands and the emerging markets.  GSK’s intention to divest its non-core Consumer assets was announced at the company’s fourth quarter 2010 results on 3rd February 2011.

The products to be divested, which are primarily sold in Europe and the United States, had sales in 2010 of approximately £500 million, 10% of GSK’s total Consumer Healthcare turnover.  They include analgesics:  Solpadeine, BC and Goody’s; vitamin and supplement product Abtei; feminine hygiene treatment Lactacyd; and alli for weight management. 

Individually, the brands to be divested have strong heritage and good prospects, but GSK has lacked sufficient critical mass in some product categories and certain brands have lacked focus due to other global priorities. GSK therefore believes that other companies are better placed to maximise the potential they offer.

The process of communicating with interested parties will begin over the next few weeks, with the aim of divesting the products by late 2011, subject to interest and realising appropriate value for shareholders.

Following the divestment, GSK’s Consumer Healthcare business will focus on three priority categories: Oral Health, Wellness/OTC and Nutrition, in which the company has fast-growing leading brands such as Sensodyne, Panadol and Horlicks.  On a pro forma basis, the retained business delivered sales of approximately £4.5 billion in 2010, and grew at 6% CAGR over the period 2007-2010. The refocused business will hold market-leading positions in Smoking Control, Denture Care, Dental Sensitivity, Analgesics, and Nutrition.  

Commenting on the proposed divestment, CEO of GSK Andrew Witty said:  “Consumer Healthcare is a key growth driver for GSK.  But it is important that we focus this business around product categories, brands and markets where we have most depth and competitive advantage, with the best prospects for strong growth.  This divestment is also an example of our commitment to focus on realising value and enhancing returns to shareholders.”

Note to editors:

Brands to be divested include the following products with sales of more than £5 million per annum.  The intention is to divest these products in all markets in which they are sold by GSK:

Abtei, vitamins, minerals and supplements

alli, weight management

Beano, gastro-intestinal

BC, analgesic

Beconase, respiratory

Debrox, ear wax cleanser

Dequadin, cough/cold

Ecotrin, analgesics

FiberChoice, dietary supplement


Goody’s, analgesics
Granufink, urological

Lactacyd, feminine hygiene

Libenar, respiratory

Nytol, sleep aid

Phillips MOM, gastro-intestinal

Solpadeine, analgesics

Tagamet/Stomedine, gastro-intestinal

Valda, cough/cold supplement

Zantac OTC, gastro-intestinal

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit

GlaxoSmithKline Enquiries:


UK Media enquiries:

David Mawdsley

(020) 8047 5502


Alexandra Harrison

(020) 8047 5502




US Media enquiries:

Nancy Pekarek

(919) 483 2839


Mary Anne Rhyne

(919) 483 2839


Kevin Colgan

(919) 483 2839


Sarah Alspach

(919) 483 2839



European Analyst/Investor enquiries:

Sally Ferguson

(020) 8047 5543


Gary Davies

(020) 8047 5503


Ziba Shamsi

(020) 8047 3289


US Analyst/ Investor enquiries:

Tom Curry

(215) 751 5419


Jeff McLaughlin

(215) 751 7002

UK Trade Media enquiries:

Emma Boran

(020) 8047 4221


Claire Dixon

(020) 8047 4296


Iona Maclean

(020) 8047 4239

US Trade Media enquiries:

Malesia Dunn

(412) 200 3544


Debbie Bolding

(973) 889 2344

GlaxoSmithKline cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK’s operations are described under ‘Risk Factors’ in the ‘Business Review’ in the company’s Annual Report on Form 20-F for 2010.

Source link